Are There Inflammatory Markers In Ehlers Danlos Syndrome?

Ehlers-Danlos syndrome (EDS) is a group of inherited connective tissue disorders, and people who live with it often hear that their pain and other symptoms are “just” mechanical. That framing is incomplete. Research has found measurable signs of immune activation and inflammation in some people with EDS, though the picture is complicated and not every marker is elevated in every person or every subtype.

The short answer: yes, inflammatory markers can be present in Ehlers-Danlos syndrome, but they are not a defining feature of the condition and they do not appear consistently across all patients or all subtypes. Some studies show elevated markers like certain cytokines and mast cell–related compounds. Others show normal routine markers such as CRP and ESR. The presence of inflammation appears to vary by subtype, by symptom pattern, and by the individual.

This matters because many people with EDS are told their labs are “normal” and left to conclude that nothing measurable is happening. The reality is that standard bloodwork may miss what is actually going on.

What Does Ehlers-Danlos Syndrome Actually Involve?

EDS is not one disease. It is a collection of at least 13 recognized subtypes, each with different genetic causes and different clinical features. The most common subtype, hypermobile EDS (hEDS), has no identified genetic marker yet. That alone makes research difficult, because scientists cannot always confirm who has it using a lab test.

The core problem in most EDS subtypes is defective collagen or related connective tissue proteins. Collagen is the structural scaffolding of skin, joints, blood vessels, and many other tissues. When it is weak or malformed, joints become unstable, skin becomes stretchy and fragile, and in some subtypes blood vessels or organs are at risk.

What EDS is not, in its primary form, is an autoimmune or inflammatory disease. That distinction matters. Autoimmune conditions happen when the immune system attacks the body’s own tissues. EDS happens because of a structural protein defect written into a person’s genes. But structural problems can trigger secondary inflammation, and that is where the research gets interesting.

Are There Inflammatory Markers In Ehlers Danlos Syndrome?

Some people with EDS do show elevated inflammatory markers, and research has documented this in several contexts. The most consistent findings involve mast cell activation and certain cytokines rather than the routine markers doctors typically order first.

Mast cells are immune cells that release histamine and other compounds during allergic and inflammatory responses. A number of studies have found a higher prevalence of mast cell activation syndrome (MCAS) in people with hEDS and hypermobility spectrum disorders than in the general population. When mast cells are overactive, they release mediators that can drive flushing, hives, gastrointestinal symptoms, and a sense of systemic inflammation.

Some research has also found elevated levels of certain cytokines — signaling proteins that immune cells use to communicate — in people with EDS. Tumor necrosis factor alpha (TNF-alpha) and interleukin-6 (IL-6) are two that have appeared in the literature. These are not the same as the standard CRP and ESR tests most doctors run.

Here is the key point: routine inflammatory markers like C-reactive protein (CRP) and erythrocyte sedimentation rate (ESR) are often normal in people with EDS. That does not mean inflammation is absent. It means the standard screening tools may not capture what is happening at the tissue or cellular level.

Which Markers Are Actually Being Studied?

Different markers tell different stories. Some reflect systemic inflammation. Others reflect immune activation or mast cell activity specifically. Understanding the difference helps explain why one person’s labs look normal while another’s do not.

• CRP and ESR — Routine markers of systemic inflammation. Often normal in EDS, which is why many patients are told nothing is wrong.
• Cytokines (TNF-alpha, IL-6, others) — Signaling molecules involved in immune and inflammatory responses. Some studies have found elevations in EDS patients, though results vary.
• Mast cell mediators (tryptase, histamine, prostaglandins) — Compounds released by mast cells. Elevated in some people with EDS and comorbid MCAS, but testing is complicated and results can be inconsistent.
• Autoantibodies — Not typically elevated in EDS itself, but sometimes present when an autoimmune condition coexists.

The presence of these markers varies widely. A person with hEDS and significant joint pain may show no elevated markers at all. Another with the same diagnosis and similar symptoms may show clear signs of immune activation. This variability is one reason EDS research remains challenging.

Why Would Inflammation Show Up In A Structural Disorder?

If EDS is caused by weak collagen, why would the immune system get involved at all? Several mechanisms may explain the connection.

First, joint instability causes repeated microtrauma. When joints move beyond their normal range, surrounding tissues get stretched, compressed, and damaged. The body responds to tissue damage with inflammation — that is normal healing physiology. Over years of recurrent injury, this can create a chronic low-grade inflammatory state.

Second, connective tissue and the immune system are not separate systems. Mast cells live in connective tissue. When the structural environment is abnormal, mast cells may behave abnormally. Some researchers have proposed that defective collagen in connective tissue affects how mast cells are anchored and regulated, potentially making them more reactive.

Third, pain itself can drive inflammation. Chronic pain conditions are associated with neuroinflammatory changes — activation of immune cells in the nervous system. This does not mean the pain is “in someone’s head.” It means the nervous system and immune system interact in ways that can perpetuate symptoms.

None of these mechanisms are fully proven. They are areas of active research. But they offer plausible explanations for why a structural condition might produce measurable immune changes.

What About Mast Cell Activation Syndrome And EDS?

The overlap between EDS, hypermobility, and mast cell activation syndrome is one of the most discussed topics in this area. Some studies have found that a meaningful proportion of people with hEDS also meet criteria for MCAS, though estimates vary and study designs differ.

MCAS symptoms can include flushing, hives, unexplained reactions to foods or environmental triggers, gastrointestinal distress, and cardiovascular changes like rapid heart rate. Many of these symptoms overlap with what people with EDS experience anyway, which makes diagnosis tricky.

Testing for MCAS is not straightforward. Tryptase levels, histamine levels, and prostaglandin metabolites can be measured, but results fluctuate and a normal result does not rule out the condition. Some clinicians use a combination of symptom history and lab findings to make a diagnosis. Others are more conservative and require clearer lab confirmation.

This is an area where clinical practice varies. Some specialists treat suspected MCAS in EDS patients with antihistamines or mast cell stabilizers. Whether this improves outcomes in EDS specifically is not well established by large trials. It is widely done in some clinical settings, but the evidence base is still developing.

Should You Get Inflammatory Markers Tested If You Have EDS?

There is no standard recommendation to routinely test inflammatory markers in all people with EDS. Whether testing makes sense depends on your symptoms and what your doctor is trying to rule out.

If you have unexplained symptoms that suggest inflammation or immune activation — persistent flushing, hives, unexplained fevers, or symptoms that do not fit the usual EDS picture — it may be reasonable to discuss further testing with your doctor. That conversation should include what markers would be checked and what the results would mean.

It is also worth remembering that normal CRP and ESR do not mean nothing is happening. They mean those particular markers are not elevated. If your doctor dismisses your symptoms based only on those two tests, it may be worth asking whether other evaluations are appropriate.

That said, chasing inflammatory markers without a clear clinical question can lead to unnecessary testing, incidental findings, and anxiety. The goal is not to prove inflammation exists. The goal is to understand your symptoms and find effective ways to manage them.

What Does This Mean For Treatment?

If inflammation is present in some people with EDS, does treating it help? The honest answer is that we do not have strong evidence that anti-inflammatory treatments improve EDS outcomes specifically.

Some clinicians use anti-inflammatory medications for symptom management, particularly for joint pain. This is common practice, but it is not the same as saying those treatments address the underlying condition. Physical therapy, joint stabilization, and pain management remain the primary approaches for most EDS subtypes.

For people with confirmed or suspected MCAS, antihistamines and mast cell stabilizers are sometimes used. Some patients report improvement. The evidence from controlled trials is limited.

No treatment currently reverses the connective tissue defect in EDS. Management focuses on protecting joints, preventing injury, and addressing symptoms. If inflammation is part of your symptom picture, it is worth discussing with a clinician who understands both EDS and immune function.